Home 
News Channels Clinical Trials
News Channels Clinical Trials
|
 World Pharma News RSS Channel
 Subscribe to World Pharma News by Email
Follow us on: |
Research & Development
Conferences & Events
- Safety Biomarkers in Drug Development Conference to be held in Bratislava, Slovak Republic
- 4th Annual Clinical Site Partnerships in Central & Eastern Europe, to be held in Budapest, Hungary
- Physicians Go Digital Across the Globe - Webinar May 19
- Emerging Superpowers of Clinical Research - Russia, India, China
Clinical Trials News Channel
Sponsored Ads |
Pharmaceutical CompaniesA | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | ZSponsored AdsPharmaceutical RSS NewsAbbott | Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda | ... European Commission - Pharmaceuticals US Food and Drug Administration Sponsored Ads
PharmaNews.eu, an advanced web based news engine, addressed to the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical news...For further information and advanced RSS channels, please visit http://www.pharmanews.eu PharmaNews.eu / Latest News |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD). 
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. 
Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC). 
Abbott (NYSE: ABT) has announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the
treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States. 
Novo Nordisk has announced the first patient visit in a new head-to-head clinical trial of once-daily Levemir® against insulin glargine. This study is the first time the two basal insulins will be directly compared in an exclusively once-daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia in type 2 diabetes patients. 
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments. 
Roche has announced that new two-year data from the LITHE study(1) demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) continues to be highly effective at inhibiting joint structural damage and maintaining consistently high remission rates. Reducing the structural damage to joints in patients with rheumatoid arthritis (RA) is a critical measure of effectiveness of an RA treatment. Financial
Product
- IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
- New biological therapy Ilaris® approved in US
- Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission
Clinical Trials
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- Sutent Significantly Improved Progression-Free Survival
- Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Corporate
- Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Bayer files patent infringement lawsuit against Teva
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs